Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NITE

Nightstar Therapeutics (NITE) Stock Price, News & Analysis

Nightstar Therapeutics logo

About Nightstar Therapeutics Stock (NASDAQ:NITE)

Advanced Chart

Key Stats

Today's Range
$31.44
$31.63
50-Day Range
$25.41
$25.41
52-Week Range
$9.59
$29.55
Volume
210 shs
Average Volume
185,808 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NITE Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
Knight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel
NITE The Nightview ETF
Thank you for supporting The Big Night In
See More Headlines

NITE Stock Analysis - Frequently Asked Questions

Nightstar Therapeutics PLC (NASDAQ:NITE) posted its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.13.

Nightstar Therapeutics (NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), OncoMed Pharmaceuticals (OMED), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals (LGND), Neurocrine Biosciences (NBIX) and Sangamo Therapeutics (SGMO).

Company Calendar

Last Earnings
11/13/2018
Today
7/15/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NITE
CIK
1711675
Fax
N/A
Employees
47
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-30.89%
Return on Assets
-27.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.54
Quick Ratio
8.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.89 per share
Price / Book
5.37

Miscellaneous

Outstanding Shares
33,540,000
Free Float
N/A
Market Cap
$1.06 billion
Optionable
Not Optionable
Beta
2.84
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NITE) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners